Design of rapamycin and resveratrol coloaded liposomal formulation for breast cancer therapy

• Main Author: Reis, Leidiana Rocha dos [UNESP]
• Publication Date: 2023
• Other Authors: Luiz, Marcela Tavares [UNESP], Sabio, Rafael M. [UNESP], Marena, Gabriel Davi [UNESP], Di Filippo, Leonardo Delello [UNESP], Duarte, Jonatas Lobato [UNESP], Fernandes, Ligia de Souza [UNESP], Araujo, Victor H. Sousa [UNESP], Silva, Viviane Aline Oliveira, Chorilli, Marlus [UNESP]
• Format: Article
• Language: eng
• Source: Repositório Institucional da UNESP
• Download full: http://dx.doi.org/10.2217/nnm-2022-0227; http://hdl.handle.net/11449/245829
• topic: codelivery; drug-delivery systems; enhanced permeability and retention effect; high-pressure homogenization; liposomes; nanomedicines; nanoparticles; nanotechnology; passive targeting

Aims: The development of rapamycin (RAP) and resveratrol (RSV) coloaded liposomes (RAP-RSV-LIP) for breast cancer therapy. Materials & methods: Liposomes were prepared using a high-pressure homogenization technique and evaluated according to their physicochemical characteristics, cellular uptake and cytotoxicity against tumoral and normal cells. Results & conclusion: The RAP-RSV-LIP showed negative surface charge, size around 100 nm, low polydispersity and high encapsulation efficiency for RAP and RSV (58.87 and 63.22%, respectively). RAP-RSV-LIP showed great stability over 60 days and a prolonged drug release profile. In vitro studies indicated that RAP-RSV-LIP were internalized in an estrogen receptor-positive human breast cancer cell line (MCF-7, 34.2%) and improved cytotoxicity when compared with free drugs. Therefore RAP-RSV-LIP showed great antitumoral potential against breast cancer cells.